Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Net Cash Flow: 2020-2025

Historic Net Cash Flow for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $21.8 million.

  • GeneDx Holdings' Net Cash Flow rose 1101.76% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 229.49%. This contributed to the annual value of -$14.5 million for FY2024, which is 61.56% up from last year.
  • Latest data reveals that GeneDx Holdings reported Net Cash Flow of $21.8 million as of Q3 2025, which was up 185.40% from -$25.6 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Net Cash Flow peaked at $424.8 million during Q3 2021, and registered a low of -$93.3 million during Q3 2022.
  • Moreover, its 3-year median value for Net Cash Flow was $1.8 million (2024), whereas its average is -$3.8 million.
  • Within the past 5 years, the most significant YoY rise in GeneDx Holdings' Net Cash Flow was 37,167.97% (2021), while the steepest drop was 5,645.63% (2021).
  • GeneDx Holdings' Net Cash Flow (Quarterly) stood at -$60.7 million in 2021, then declined by 11.07% to -$67.4 million in 2022, then surged by 118.36% to $12.4 million in 2023, then surged by 120.67% to $27.3 million in 2024, then spiked by 1,101.76% to $21.8 million in 2025.
  • Its last three reported values are $21.8 million in Q3 2025, -$25.6 million for Q2 2025, and $14.5 million during Q1 2025.